DOI: https://dx.doi.org/10.18565/therapy.2023.5.26-31
Romanova T.V., Poverennova I.E., Persteneva N.P.
1) Samara State Medical University of the Ministry of Healthcare of Russia; 2) Samara State University of Economics of the Ministry of education and science of Russia
1. Санадзе А.Г. Миастения и миастенические синдромы. М.: ГЭОТАР-Медиа. 2017; 256 с. [Sanadze А.G. Myasthenia gravis and myasthenic syndromes. Moscow: GEOTAR-Media. 2017; 256 рp. (In Russ.)]. ISBN: 978-5-9704-4026-1. 2. Estephan E.P., Baima J.P.S., Zambon A.A. Myasthenia gravis in clinical practice. Arq Neuropsiquiatr. 2022; 80(5 Suppl 1): 257–65. https://dx.doi.org/10.1590/0004-282X-ANP-2022-S105. 3. Романова Т.В., Калашникова В.В., Романов Д.В. Реабилитационный потенциал больных миастенией. Саратовский научно-медицинский журнал. 2020; 16(1): 371–377. [Romanova T.V., KalashnikovaV.V., Romanov D.V. Rehabilitation potential of patient with myasthenia gravis. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Journal of Medical Scientific Research. 2020; 16(1): 371–377 (In Russ.)]. EDN: FRWHHS. 4. Антипенко Е.А., Лапшина О.В., Седышев Д.В. Возможности оптимизации терапии миастении гравис. Нервные болезни. 2022; (4): 54–56. [Antipenko E.A., Lapshina O.V., Sedyshev D.V. Opportunities for optimizing the therapy of myasthenia gravis. Nervnye bolezni = Nervous Diseases. 2022; (4): 54–56 (In Russ)]. https://dx.doi.org/10.24412/2226-0757-2022-12935. EDN: MQTPWH. 5. Bubuioc A.M., Kudebayeva A., Turuspekova S. et al. The epidemiology of myasthenia gravis. J Med Life. 2021; 14(1): 7–16. https://dx.doi.org/10.25122/jml-2020-0145. 6. Hehir M.K., Silvestri N.J. Generalized myasthenia gravis: Classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018; 36(2): 253–60. https://dx.doi.org/10.1016/j.ncl.2018.01.002. 7. Farmakidis C., Pasnoor M., Dimachkie M.M., Barohn R.J. Treatment of myasthenia gravis. Neurol Clin. 2018; 36(2): 311–37. https://dx.doi.org/10.1016/j.ncl.2018.01.011. 8. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. NatClinPractNeurol. 2008; 4(6): 317–27. https://dx.doi.org/10.1038/ncpneuro0810. 9. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5): 475–90. https://dx.doi.org/10.1016/S1474-4422(09)70063-8. 10. Gilhus N.E., Tzartos S., Evoli A. et al. Myasthenia gravis. Nat Rev Dis Primers. 2019; 5(1): 30. https://dx.doi.org/10.1038/s41572-019-0079-y. 11. Nagane Y., Suzuki S., Suzuki N. et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011; 65(1): 16–22. https://dx.doi.org/10.1159/000322497. 12. Imai T., Suzuki S., Tsuda E. et al. Oral corticosteroid therapy and present disease status in myasthenia gravis. MuscleNerve. 2015; 51(5): 692–96. https://dx.doi.org/10.1002/mus.24438 13. Sussman J., Farrugia M., Maddison P. et al. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol. 2015; 15(3): 199–206. https://dx.doi.org/10.1136/practneurol-2015-001126. 14. Sanders D.B., Wolfe G.I., Benatar M. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016; 87(4): 419–25. https://dx.doi.org/10.1212/WNL.0000000000002790. 15. Jaretzki A.I., Barohn R.J., Ernstoff R.M. Myasthenia gravis: Recommendations for clinical research standards. Neurology. 2000; 55(1): 16–23. https://dx.doi.org/10.1212/wnl.55.1.16. 16. Barnett C., Herbelin L., Dimachkie M.M., Barohn R.J. Measuring clinical treatment response in myasthenia gravis. Neurol Clin. 2018; 36(2): 339–53. https://dx.doi.org/10.1016/j.ncl.2018.01.006. 17. Nagane Y., Suzuki S., Suzuki N. et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol. 2011; 65(1): 16–22. https://dx.doi.org/10.1159/000322497. 18. Lascano A.M., Lalive P.H. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021:20(1):102712. https://dx.doi.org/10.1016/j.autrev.2020.102712. 19. Hehir M.K. 2nd, Li Y. Diagnosis and management of myasthenia gravis. Continuum (Minneap Minn). 2022; 28(6): 1615–42. https://dx.doi.org/10.1212/CON.0000000000001161.
Tatyana V. Romanova, MD, associate professor, professor of the Department of neurology and neurosurgery, Samara State Medical University of the Ministry of Healthcare of Russia. Address: 443099, Samara, 89 Chapaevskaya Str. E-mail: tvrom63@mail.ru. ORCID: https://orcid.org/0000-0003-2851-8672
Irina E. Poverennova, MD, professor, head of the Department of neurology and neurosurgery, Samara State Medical University of the Ministry of Healthcare of Russia. Address: 443099, Samara, 89 Chapaevskaya Str. E-mail: ipover555@mail.ru. ORCID: https://orcid.org/0000-0002-2594-461X.
Natalya P. Persteneva, PhD in Economics, associate professor of the Department of statistics and econometrics, Samara State University of Economics of the Ministry of education and science of Russia. Address: 443090, Samara, 141 Sovetskoy armii Str. E-mail: persteneva_np@mail.ru. ORCID: https://orcid.org/0000-0003-3845-5011